Search results for "Fixed-dose rate"

showing 1 items of 1 documents

A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

2011

<i>Background:</i> This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients. <i>Methods:</i> Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and measurable disease were enrolled. Treatment consisted of FDR gemcitabine at 800 mg/m<sup>2</sup> on days 1 and 8 every 21 days with capecitabine administered orally b.i.d. in equal doses (650 mg/m<sup>2</sup> b.i.d.) for 14 days (28 doses). <i>…

OncologyMaleCancer Researchmedicine.medical_specialtyDisease free survivalSettore MED/06 - Oncologia MedicaDeoxycytidineDisease-Free SurvivalCapecitabineBiliary tract cancer; Capecitabine; Fixed-dose rate; GemcitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisCapecitabineAgedNeoplasm StagingBiliary tract cancerFixed-dose ratebusiness.industryGeneral MedicineFixed dose rateMiddle AgedGemcitabineGemcitabineClinical trialBiliary Tract NeoplasmsOncologyBiliary tract cancerNeoplasm stagingFemaleFluorouracilbusinessmedicine.drug
researchProduct